OperaV1, PascalFrancis, Curation, bibRecord, 000200

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

Identifieur interne : 000200 ( PascalFrancis/Curation ); précédent : 000199; suivant : 000201

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

Auteurs : S. M. Pöykkö [Finlande] ; O. Ukkola [Finlande] ; H. Kauma [Finlande] ; E. Kellokoski [Finlande] ; S. Hörkkö [Finlande] ; Y. A. Kes Niemi [Finlande]

Source :

Diabetologia : (Berlin) [ 0012-186X ] ; 2005.

RBID : Pascal:05-0187795

Descripteurs français

Pascal (Inist)
- Association, Ghréline, Facteur croissance IGF1, Obésité, Hormone, Protéine liaison IGFBP, Insulinoresistance, Etat nutritionnel, Diabète type 2.
Wicri :
- topic : Association, Hormone.

English descriptors

KwdEn :
- Association, Ghrelin, Hormone, Insulin like growth factor 1, Insulin like growth factor binding protein, Insulin resistance, Nutritional status, Obesity, Type 2 diabetes.

Abstract

Aims/hypothesis: Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association. Methods: We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middle-aged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI. Results: IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β= -0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=-0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r²=6.5% (p<0.001), insulin resistance without type 2 diabetes: r²=21.0% (p< 0.001), type 2 diabetes: r²=25.4 (p<0.001). IGF-I levels explained larger proportion (r²=9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r²=3.0%) and BMI (r²=1.5%). Conclusions/ interpretation: There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.

A01	`01`	`1`		`@0 0012-186X`
A03		`1`		`@0 Diabetologia : (Berl.)`
A05				`@2 48`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes`
A11	`01`	`1`		`@1 PÖYKKÖ (S. M.)`
A11	`02`	`1`		`@1 UKKOLA (O.)`
A11	`03`	`1`		`@1 KAUMA (H.)`
A11	`04`	`1`		`@1 KELLOKOSKI (E.)`
A11	`05`	`1`		`@1 HÖRKKÖ (S.)`
A11	`06`	`1`		`@1 KESÄNIEMI (Y. A.)`
A14	`01`			`@1 Department of Internal Medicine, University of Oulu, P.O. Box 5000 @2 90014 Oulu @3 FIN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 309-316`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 13012 @5 354000126266030160`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 58 ref.`
A47	`01`	`1`		`@0 05-0187795`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Diabetologia : (Berlin)`
A66	`01`			`@0 DEU`
C01	`01`		`ENG`	@0 Aims/hypothesis: Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association. Methods: We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middle-aged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI. Results: IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β= -0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=-0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r²=6.5% (p<0.001), insulin resistance without type 2 diabetes: r²=21.0% (p< 0.001), type 2 diabetes: r²=25.4 (p<0.001). IGF-I levels explained larger proportion (r²=9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r²=3.0%) and BMI (r²=1.5%). Conclusions/ interpretation: There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.
C02	`01`	`X`		`@0 002B21E01`
C02	`02`	`X`		`@0 002B22B`
C03	`01`	`X`	`FRE`	`@0 Association @5 01`
C03	`01`	`X`	`ENG`	`@0 Association @5 01`
C03	`01`	`X`	`SPA`	`@0 Asociación @5 01`
C03	`02`	`X`	`FRE`	`@0 Ghréline @5 02`
C03	`02`	`X`	`ENG`	`@0 Ghrelin @5 02`
C03	`02`	`X`	`SPA`	`@0 Grelina @5 02`
C03	`03`	`X`	`FRE`	`@0 Facteur croissance IGF1 @5 03`
C03	`03`	`X`	`ENG`	`@0 Insulin like growth factor 1 @5 03`
C03	`03`	`X`	`SPA`	`@0 Factor crecimiento IGF1 @5 03`
C03	`04`	`X`	`FRE`	`@0 Obésité @5 04`
C03	`04`	`X`	`ENG`	`@0 Obesity @5 04`
C03	`04`	`X`	`SPA`	`@0 Obesidad @5 04`
C03	`05`	`X`	`FRE`	`@0 Hormone @5 07`
C03	`05`	`X`	`ENG`	`@0 Hormone @5 07`
C03	`05`	`X`	`SPA`	`@0 Hormona @5 07`
C03	`06`	`X`	`FRE`	`@0 Protéine liaison IGFBP @5 08`
C03	`06`	`X`	`ENG`	`@0 Insulin like growth factor binding protein @5 08`
C03	`06`	`X`	`SPA`	`@0 Proteína enlace IGFBP @5 08`
C03	`07`	`X`	`FRE`	`@0 Insulinoresistance @2 NM @5 09`
C03	`07`	`X`	`ENG`	`@0 Insulin resistance @2 NM @5 09`
C03	`07`	`X`	`SPA`	`@0 Resistancia insulina @2 NM @5 09`
C03	`08`	`X`	`FRE`	`@0 Etat nutritionnel @5 10`
C03	`08`	`X`	`ENG`	`@0 Nutritional status @5 10`
C03	`08`	`X`	`SPA`	`@0 Estado nutricional @5 10`
C03	`09`	`X`	`FRE`	`@0 Diabète type 2 @2 NM @5 12`
C03	`09`	`X`	`ENG`	`@0 Type 2 diabetes @2 NM @5 12`
C03	`09`	`X`	`SPA`	`@0 Diabetes de tipo 2 @2 NM @5 12`
C07	`01`	`X`	`FRE`	`@0 Métabolisme pathologie @5 20`
C07	`01`	`X`	`ENG`	`@0 Metabolic diseases @5 20`
C07	`01`	`X`	`SPA`	`@0 Metabolismo patología @5 20`
C07	`02`	`X`	`FRE`	`@0 Trouble nutrition @5 21`
C07	`02`	`X`	`ENG`	`@0 Nutrition disorder @5 21`
C07	`02`	`X`	`SPA`	`@0 Trastorno nutricíon @5 21`
C07	`03`	`X`	`FRE`	`@0 Endocrinopathie @5 38`
C07	`03`	`X`	`ENG`	`@0 Endocrinopathy @5 38`
C07	`03`	`X`	`SPA`	`@0 Endocrinopatía @5 38`
N21				`@1 129`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000403

Links to Exploration step

Pascal:05-0187795

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes</title>
<author><name sortKey="Poykko, S M" sort="Poykko, S M" uniqKey="Poykko S" first="S. M." last="Pöykkö">S. M. Pöykkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kauma, H" sort="Kauma, H" uniqKey="Kauma H" first="H." last="Kauma">H. Kauma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kellokoski, E" sort="Kellokoski, E" uniqKey="Kellokoski E" first="E." last="Kellokoski">E. Kellokoski</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Horkko, S" sort="Horkko, S" uniqKey="Horkko S" first="S." last="Hörkkö">S. Hörkkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0187795</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0187795 INIST</idno>
<idno type="RBID">Pascal:05-0187795</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000403</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000200</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes</title>
<author><name sortKey="Poykko, S M" sort="Poykko, S M" uniqKey="Poykko S" first="S. M." last="Pöykkö">S. M. Pöykkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Ukkola, O" sort="Ukkola, O" uniqKey="Ukkola O" first="O." last="Ukkola">O. Ukkola</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kauma, H" sort="Kauma, H" uniqKey="Kauma H" first="H." last="Kauma">H. Kauma</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kellokoski, E" sort="Kellokoski, E" uniqKey="Kellokoski E" first="E." last="Kellokoski">E. Kellokoski</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Horkko, S" sort="Horkko, S" uniqKey="Horkko S" first="S." last="Hörkkö">S. Hörkkö</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
<author><name sortKey="Kes Niemi, Y A" sort="Kes Niemi, Y A" uniqKey="Kes Niemi Y" first="Y. A." last="Kes Niemi">Y. A. Kes Niemi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Finlande</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Diabetologia : (Berlin)</title>
<title level="j" type="abbreviated">Diabetologia : (Berl.)</title>
<idno type="ISSN">0012-186X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Association</term>
<term>Ghrelin</term>
<term>Hormone</term>
<term>Insulin like growth factor 1</term>
<term>Insulin like growth factor binding protein</term>
<term>Insulin resistance</term>
<term>Nutritional status</term>
<term>Obesity</term>
<term>Type 2 diabetes</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Association</term>
<term>Ghréline</term>
<term>Facteur croissance IGF1</term>
<term>Obésité</term>
<term>Hormone</term>
<term>Protéine liaison IGFBP</term>
<term>Insulinoresistance</term>
<term>Etat nutritionnel</term>
<term>Diabète type 2</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Association</term>
<term>Hormone</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Aims/hypothesis: Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association. Methods: We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middle-aged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI. Results: IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β= -0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=-0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r<sup>2</sup>
=6.5% (p<0.001), insulin resistance without type 2 diabetes: r<sup>2</sup>
=21.0% (p< 0.001), type 2 diabetes: r<sup>2</sup>
=25.4 (p<0.001). IGF-I levels explained larger proportion (r<sup>2</sup>
=9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r<sup>2</sup>
=3.0%) and BMI (r<sup>2</sup>
=1.5%). Conclusions/ interpretation: There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0012-186X</s0>
</fA01>
<fA03 i2="1"><s0>Diabetologia : (Berl.)</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PÖYKKÖ (S. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>UKKOLA (O.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KAUMA (H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KELLOKOSKI (E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HÖRKKÖ (S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KESÄNIEMI (Y. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Internal Medicine, University of Oulu, P.O. Box 5000</s1>
<s2>90014 Oulu</s2>
<s3>FIN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>309-316</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13012</s2>
<s5>354000126266030160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>58 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0187795</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Diabetologia : (Berlin)</s0>
</fA64>
<fA66 i1="01"><s0>DEU</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Aims/hypothesis: Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association. Methods: We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middle-aged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI. Results: IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β= -0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=-0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r<sup>2</sup>
=6.5% (p<0.001), insulin resistance without type 2 diabetes: r<sup>2</sup>
=21.0% (p< 0.001), type 2 diabetes: r<sup>2</sup>
=25.4 (p<0.001). IGF-I levels explained larger proportion (r<sup>2</sup>
=9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r<sup>2</sup>
=3.0%) and BMI (r<sup>2</sup>
=1.5%). Conclusions/ interpretation: There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B21E01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B22B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Association</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Association</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Asociación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ghréline</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ghrelin</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Grelina</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Facteur croissance IGF1</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Insulin like growth factor 1</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Factor crecimiento IGF1</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Obésité</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Obesity</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Obesidad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Hormone</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Hormone</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hormona</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Protéine liaison IGFBP</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Insulin like growth factor binding protein</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Proteína enlace IGFBP</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Insulinoresistance</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Insulin resistance</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Resistancia insulina</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etat nutritionnel</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Nutritional status</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estado nutricional</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Diabète type 2</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Type 2 diabetes</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Diabetes de tipo 2</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Métabolisme pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metabolic diseases</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metabolismo patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Trouble nutrition</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nutrition disorder</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Trastorno nutricíon</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Endocrinopathie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Endocrinopathy</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Endocrinopatía</s0>
<s5>38</s5>
</fC07>
<fN21><s1>129</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000200 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000200 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:05-0187795
   |texte=   The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri